Filing Details
Alzamend Neuro, Inc. (NASDAQ:ALZN) filed its annual report (Form 10-K) with the Securities and Exchange Commission on July 22, 2026.
The Healthcare company's annual report covers fiscal year 2026.
10k filedNASDAQ:ALZN
Alzamend Neuro, Inc. (ALZN) Files Annual Report with SEC
Filing Details Alzamend Neuro, Inc. (NASDAQ:ALZN) filed its annual report (Form 10-K) with the Securities and Exchange Commission on July 22, 2026. The Healthcare company's annual…
Market Context
Alzamend Neuro, Inc.'s stock currently trades at $1.35 with a market capitalization of $6.3M.
The 10-K is the most comprehensive annual report a public company files, containing detailed financial statements, management discussion and analysis (MD&A), risk factors, and business segment breakdowns. For Alzamend Neuro, Inc. investors, the 10-K provides depth that quarterly reports don't — including full-year trends, long-term debt schedules, and off-balance-sheet items.
Key sections to review: MD&A for management's narrative on performance, risk factors for newly disclosed threats, and the notes to financial statements for accounting changes that could affect reported earnings.
All SEC filings for Alzamend Neuro, Inc. are publicly available through the SEC's EDGAR database. Investors can set up alerts for new filings to stay current on material developments.
Related Tools: View ALZN Stock Page
Frequently Asked Questions
Where can I read ALZN's SEC filings?
Browse all filings on our ALZN SEC filings page.
What types of SEC filings does Alzamend Neuro, Inc. file?
Public companies like Alzamend Neuro, Inc. file annual reports (10-K), quarterly reports (10-Q), material events (8-K), and insider transactions (Form 4) with the SEC.